Change over period: —
NSE · VALIANTLAB
VALIANTLAB
-29.8% from the 52-week high · +94.0% above the low
Valiant Laboratories Ltd manufactures pharmaceuticals, chemicals, and healthcare products. The company serves hospitals, clinics, and industrial clients with quality-driven manufacturing and regulatory compliance.
The short version. VALIANTLAB reported revenue of ₹117 crore for Sep 2026, up 154.3% from a year earlier. Return on equity was -1.1% in Mar 2026. Promoter holding was 74.94% in Sep 2026, up 0.00 points over 8 quarters.
1 · The price
How has the stock traded?
VALIANTLAB trades 29.8% below its 52-week high and 94.0% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹117 cr.
Unchanged from a year earlier.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 117 | 115 | 92 | 52 | 46 | 47 | 58 | 35 |
| Net profit | 0 | 21 | 2 | -7 | 0 | 2 | 1 | 2 |
| Net margin % | 0.4 | 18.3 | 1.9 | -13.5 | 0.4 | 3.9 | 1.2 | 6.7 |
| EPS (₹) | 0.08 | 3.89 | 0.32 | -1.3 | 0.04 | 0.34 | 0.13 | 0.43 |
Annual
| FY2026 | FY2025 | FY2024 | |
|---|---|---|---|
| Revenue | 237 | 133 | 182 |
| Net profit | -3 | -2 | 0 |
| Net margin % | -1.4 | -1.7 | 0.2 |
| EPS (₹) | -0.6 | -0.41 | 0.06 |
3 · The quality
How well does it turn capital into profit?
Return on equity was -1.1% in Mar 2026; debt to equity is 0.14.
Profitability · 3 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | |
|---|---|---|---|
| Return on equity % | -1.1 | -0.9 | 0.1 |
| Return on capital % | 0.8 | -0.4 | -0.2 |
| EBITDA margin % | 3.6 | 0.5 | 0.7 |
| Net margin % | -1.4 | -1.6 | 0.2 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | — | — |
| Profit CAGR | — | — |
4 · The owners
Who holds it, and are they adding?
Unchanged over 8 quarters.
Up 0.07 pts over 8 quarters.
Up 0.08 pts over 8 quarters.
+0 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 74.94 | 74.94 | 74.94 | 74.94 | 74.94 | 74.94 | 74.94 | 74.94 | 0.0 |
| FII | 0 | 0.64 | 0.63 | 0.02 | 0.01 | 0.2 | 0 | 0.07 | +0.07 |
| DII | 0 | 0 | 0.46 | 0 | 0 | 0 | 0 | 0.08 | +0.08 |
| Public | 25.06 | 24.42 | 23.97 | 25.04 | 25.05 | 24.86 | 25.06 | 24.91 | -0.15 |
Mutual fund holdings · Oct 2026
0 schemes hold this stock
0 the month before.
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for VALIANTLAB are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Pharmaceuticals & Biotechnology stocks
Quick answers
Common questions about VALIANTLAB
What is the VALIANTLAB share price?
VALIANTLAB (VALIANTLAB) last closed at ₹96.84, down 1.99% on the day. Its 52-week range is ₹50.93 to ₹140.75.
What is the market cap of VALIANTLAB?
VALIANTLAB has a market capitalisation of about ₹561 crore. Its price-to-earnings ratio is 34.2.
How are VALIANTLAB's latest results?
VALIANTLAB reported revenue of ₹117 crore for Sep 2026, up 154.3% from a year earlier. Return on equity was -1.1% in Mar 2026. Promoter holding was 74.94% in Sep 2026, up 0.00 points over 8 quarters.
Who owns VALIANTLAB?
As of Sep 2026, shareholding was: Promoter 74.94%, FII 0.07%, DII 0.08%, Public 24.91%.
How many mutual funds hold VALIANTLAB?
0 mutual fund schemes held VALIANTLAB in October 2026. That compares with 0 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 18 Jul 2025 · Rights issue 1:4
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.